Previous Article | Next Article 
Molecular and Cellular Biology, July 1999, p. 4611-4622, Vol. 19, No. 7
0270-7306/99/$04.00+0
Ras-Specific Exchange Factor GRF: Oligomerization through Its Dbl
Homology Domain and Calcium-Dependent Activation of Raf
Pieter H.
Anborgh,
Xiaolan
Qian,
Alex G.
Papageorge,
William
C.
Vass,
Jeffrey E.
DeClue, and
Douglas R.
Lowy*
Laboratory of Cellular Oncology, National
Cancer Institute, Bethesda, Maryland 20892
Received 8 February 1999/Returned for modification 15 March
1999/Accepted 1 April 1999
 |
ABSTRACT |
The full-length versions of the Ras-specific exchange factors
Ras-GRF1 (GRF1) and Ras-GRF2 (GRF2), which are expressed in brain and a
restricted number of other organs, possess an ionomycin-dependent activation of Erk mitogen-activated protein kinase activity in 293T
cells (C. L. Farnsworth et al., Nature 376:524-527, 1995; N. P. Fam et al., Mol. Cell. Biol. 17:1396-1406, 1996). Each GRF protein
contains a Dbl homology (DH) domain. A yeast two-hybrid screen was used
to identify polypeptides that associate with the DH domain of GRF1. In
this screen, a positive cDNA clone from a human brain cDNA library was
isolated which consisted of the GRF2 DH domain and its adjacent
ilimaquinone domain. Deletion analysis verified that the two-hybrid
interaction required only the DH domains, and mutation of Leu-263 to
Gln (L263Q) in the N terminus of the GRF1 DH domain abolished the
two-hybrid interaction, while a cluster of more C-terminally located
mutations in the DH domain did not eliminate the interaction. Oligomers
between GRF1 and GRF2 were detected in a rat brain extract, and forced expression of GRF1 and GRF2 in cultured mammalian cells formed homo-
and hetero-oligomers. Introduction of the L263Q mutation in GRF1 led to
a protein that was deficient in oligomer formation, while GRF1
containing the DH cluster mutations formed homo-oligomers with an
efficiency similar to that of wild type. Compared to wild-type GRF1,
the focus-forming activity on NIH 3T3 cells of the GRF1 DH cluster
mutant was reduced, while the L263Q mutant was inactive. Both mutants
were impaired in their ability to mediate ionomycin-dependent Erk
activity in 293T cells. In the absence of ionomycin, 293T cells
expressing wild-type GRF1 contained much higher levels of Ras-GTP than
control cells; the increase in Erk activity induced by ionomycin in the
GRF1-expressing cells also induced a concomitant increase in Raf kinase
activity, but without a further increase in the level Ras-GTP. We
conclude that GRF1 and GRF2 can form homo- and hetero-oligomers via
their DH domains, that mutational inactivation of oligomer formation by
GRF1 is associated with impaired biological and signaling activities,
and that in 293T cells GRF1 mediates at least two pathways for Raf
activation: one a constitutive signal that is mainly Ras-dependent, and
one an ionomycin-induced signal that cooperates with the constitutive signal without further augmenting the level of GTP-Ras.
 |
INTRODUCTION |
Ras GTPases, which play a pivotal role
as transducers of various mitogenic and differentiation signals,
function as molecular switches, cycling between an inactive GDP-bound
state and an active GTP-bound state (33). Ras is negatively
regulated by GTPase-activating proteins (ras GAPs) that stimulate
hydrolysis of GTP-Ras to GDP-Ras. The conversion of the GDP-bound form
into the active form is stimulated by Ras-specific guanine nucleotide
exchange factors (GNEFs), such as Ras-GRF (GRF, also known previously
as CDC25Mm) (10, 44), Sos (45), and
Ras-GRP (13, 48). GNEFs function by inducing release of
bound GDP from Ras, which results in the rapid binding of GTP, because
the concentration of free GTP is much higher than that of free GDP, and
Ras has a greater affinity for GTP than for GDP (31). Ras
contains several direct downstream targets, including Raf, which in
turn activate the Mek and Erk mitogen-activated protein (MAP) kinases
(7).
Mammals contain two closely related sos genes,
sos1 and sos2 (4), as well as two
grf genes which encode homologous proteins, GRF1 and GRF2,
respectively (17). While Sos1 and Sos2 are ubiquitously expressed, full-length GRF1 and GRF2 are primarily brain specific, although the full-length protein and various smaller forms have also
been observed in other tissues (17, 21, 27, 43, 44, 50).
Functionally, GRF1 has been implicated in synaptic transmission and the
formation of long-term memory (5), in agreement with its
presence in synaptic junctions (47). In mice grf1
has been shown to be imprinted, with only the paternal gene being
expressed (40). Animals lacking detectable GRF1 protein are
viable but grow more slowly than controls, presumably because of a
hypothalamic defect, which is associated with low levels of circulating
insulin-like growth factor 1 (30).
Full-length GRF1 is a 140-kDa protein with many motifs common to other
signaling molecules (Fig. 1). In addition to
its C-terminally located Ras-catalytic domain, which is responsible for
the stimulation of the guanine nucleotide exchange on Ras, GRF contains
an N-terminal pleckstrin homology (PH) domain, a coiled-coil (CC)
motif, an ilimaquinone (IQ) motif, a Dbl homology (DH) domain adjacent
to a second PH domain, and a PEST motif. The N-terminal PH domain of
GRF1 has been shown to bind the 
subunit of heterotrimeric G
proteins in vitro (49), and Mattingly and Macara have
reported a phosphorylation-dependent activation of GRF1 by muscarinic
receptors through the 
subunit of a heterotrimeric G protein
(37). The influx of calcium in human 293T cells, via the
calcium ionophore ionomycin, has also been shown to activate GRF1, as
measured primarily by an increased Erk1 activity that can be suppressed
by a dominant inhibitory Ras mutant (19). The
calcium-dependent activation is associated with the binding of
calmodulin to the IQ motif, which acts cooperatively with the other
motifs in the N terminus of GRF1, including both PH domains as well as
the CC and DH domains (6, 24). A PEST-like region renders
the protein susceptible in vitro to cleavage by calpain, although it is
not clear if this cleavage also occurs in vivo (2).
Ionomycin-dependent Erk1 activation has also been reported for GRF2,
which is structurally similar to GRF1 (17).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of the domain structure of GRF1
and of the baits and preys used in the two-hybrid interactions. The
various abbreviations are as defined in the text; PEST is the protein
instability motif, and Catalytic refers to the Ras guanine nucleotide
exchange domain. In the bait fusions, Gal4BD represents the
Gal4-binding domain (BD), while Gal4AD represents the Gal4 activation
domain (AD) in the prey fusions. The numbers in parentheses refer to
the corresponding amino acid residues of full-length mGRF1 encoded in
the bait fusions and of full-length hGRF2 in the prey fusions.
BD-mGRF1(221-497) is the starting bait fusion used in the two-hybrid
screen. BD-mGRF1(221-460) lacks the PH domain codons in
BD-mGRF1(221-497). BD-mGRF(221-497)IIIRDII harbors a cluster of
substitutions in codons 394 to 400, while BD-mGRF1(221-497)L263Q
contains a point mutation (see the text). AD-hGRF2(176-474) is the
insert from clone pGAD10.56 obtained in the two-hybrid screen. In
AD-hGRF2(234-474), the IQ motif codons have been deleted from the
hGRF2 insert obtained in the two-hybrid screen.
|
|
The precise function of the GRF1 DH domain has not been determined. The
c-Dbl oncoprotein is the prototype for signaling proteins that contain
a DH domain (11). c-Dbl acts as a GNEF for two Rho family
GTPases, Cdc42 and RhoA (39). Members of the Rho family of
GTPases, which include Rac in addition to CDC42 and Rho, play important
roles in mediating various cytoskeletal reorganizations in cells
(52). The DH domain of c-Dbl is responsible for its exchange
activity in vitro (28). It is believed that other Dbl family
members also serve as GNEFs for one or more Rho family GTPases,
although this ability has been shown for only a subset of DH domains
(39). Mouse GRF2 has been recently shown to display in vitro
exchange activity toward Rac (18). However, analogous attempts to show that GRF1 displays exchange activity towards any of
the known Rho family GTPases have thus far yielded negative results
(11a, 24).
In this study, we included the DH domain of GRF1 as a bait in a yeast
two-hybrid screen to identify protein(s) that may interact with this
region. We report that the screen unexpectedly identified the DH domain
of GRF2 as functionally interacting with the DH domain of GRF1 and
that, in mammalian cells, GRF1 and GRF2 formed homo-oligomers as well
as hetero-oligomers with each other. We also observed a calcium induced
GRF1-dependent Erk activation that was associated with increased Ras
activity but, surprisingly, was not correlated with a further increase
in GTP-Ras. A point mutation in the DH domain reduced each of these
GRF1-dependent activities, as well as the GRF1-dependent cell transformation.
 |
MATERIALS AND METHODS |
Plasmid constructions.
The construction of the bait for the
two-hybrid screen was as follows: a 0.8-kb PCR product encoding the Dbl
homology domain and flanking regions of mGRF1 (amino acids 221 to 497)
was synthesized by using Pfu DNA polymerase (Stratagene)
with the primers JD79 (GGGGATCCTGTGCCGGCGAAAGTGGAAG)
and JD80 (CCGTCGACTCAGAAACACTGGCGCTCACCCTC). The underlined nucleotides indicate a BamHI site and a
SalI site, respectively. The fragment was subcloned into
pAS1 by using these enzymes to generate pAS1GRFdbl. This plasmid
contains the ADH promoter that directs the synthesis of a
fusion between the DNA-binding domain of GAL4 (amino acids 1 to 147)
and the Dbl homology domain of mGRF1. The mutation changing a leucine
residue to a glutamine at position 263 of mGRF1 was created by overlap
PCR according to standard techniques. Constructs were verified by DNA
sequencing by using Sequenase 2.0 (Amersham). Expression of
Gal4-binding domain fusion proteins in yeast strain Y190 was verified
by immunoblotting with anti-GAL4 antibodies (Upstate Biotechnology,
Inc.). For expression in mammalian cells, full-length wild-type or
mutated grf genes were cloned into pEFP (41). For
expression as glutathione S-transferase (GST) fusion
proteins in mammalian cells, grf genes were cloned into pEBG
(obtained from Silvio Gutkind, National Institutes of Health).
Two-hybrid screening.
The yeast strain Y190 and plasmids
pAS1 and pSE1112 (12) were provided by S. Elledge (Baylor
College, Houston, Tex.). A human brain cDNA library in the pGAD10
vector, used in the two-hybrid screen, was purchased from Clontech.
pGAD10 contains the ADH promoter expressing the GAL4
transactivation domain (amino acids 768 to 881). The yeast reporter
strain Y190 harbors two reporter gene constructs. Two-hybrid
interactions activate the transcription of the HIS3 gene, allowing
screening for growth in the absence of histidine, and of the
lacZ gene, allowing screening for
-galactosidase activity. Y190 was cotransformed with pAS1GRFdbl and the pGAD10-human brain cDNA library and plated at a density of 5 × 104
colonies per plate on synthetic minimal medium lacking leucine and
tryptophan (for plasmid selection) and histidine but containing 25 mM
3-aminotriazole. The plates were incubated at 30°C for 5 to 7 days.
Colonies that grew on these plates were transferred to fresh selective
plates and assayed for
-galactosidase activity by a filter assay.
Liquid
-galactosidase assays were conducted according to standard
procedures (26).
GRF2 GenBank accession number and analysis of tissue samples for
GRF mRNA and protein.
The GenBank accession number for human GRF2
is AF023130. Two cDNA templates were prepared by PCR for the detection
of GRF1 and GRF2, respectively, in various human tissues. For hGRF1 the sequence of the probe corresponded to amino acids Asn-780-Leu-902. For
hGRF2 the probe corresponded to Ser-763-Ala-879. The probes, chosen
from regions that bear little homology between the two proteins, were
labeled with [
-32P]dCTP by random priming by using the
Rediprime kit (Amersham) according to the manufacturer's instructions
and hybridized to the membrane in ExpresHyb solution (Clontech) at
68°C for 1 h. Subsequently, the blots were washed twice in 2×
SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.05% sodium
dodecyl sulfate (SDS) buffer at room temperature, washed in 0.1×
SSC-0.1% SDS at 55°C, and autoradiographed. Northern blots,
containing approximately 2 µg of the indicated poly(A)+
RNA in each lane, were purchased from Clontech (blots MTN-1 and MTN-2).
Blots were first hybridized with the hGRF2 probe, stripped by
incubation in 0.5% SDS at 95°C for 10 min, hybridized with the hGRF1
probe, stripped again, and finally hybridized to an actin probe to
verify equal loading of poly(A)+ RNA in each lane.
For hGRF2 antibody preparation, a peptide corresponding to amino acid
residues 183 to 200 of human GRF2, which was chosen
because it shared
only one amino acid residue with GRF1, was coupled
to bovine serum
albumin (BSA) by using the Imject Activated Immunogen
conjugation kit
(Pierce). The BSA-conjugated peptide was used
to immunize rabbits by
subcutaneous injection. Preliminary experiments
indicated that it
detects human and rodent GRF2 protein but not
rodent GRF1 protein. For
detection of GRF2, 75 µg of SDS-solubilized
proteins from human
tissues (brain, kidney, lung, liver, and heart;
all from Clontech) were
fractionated by SDS-polyacrylamide gel
electrophoresis (PAGE) and
electroblotted onto polyvinylidine
difluoride (PVDF) membranes.
Membranes were incubated with anti-GRF2
serum and then with
125I-conjugated goat-anti rabbit immunoglobulin G (ICN).
Autoradiography
was carried out at

70°C for 2
days.
Analysis of homo- and hetero-oligomerization of GRF1 and
GFR2.
NIH 3T3 and 293T cells were transiently transfected with DNA
constructs encoding GRF1 or GRF2 with or without a GST tag. At 24 h after transfection, NIH 3T3 cells were metabolically labeled with
[35S]methionine (150 µCi/ml; NEN-Dupont) in
methionine-free medium for 2 h and chased with Dulbecco modified
Eagle medium (DMEM) containing 5% fetal bovine serum (FBS) for another
3 h. The cells were lysed with nondenaturing lysis buffer after
two washes with cold phosphate-buffered saline (PBS). Equal amounts of
labeled protein, estimated by obtaining trichloroacetic
acid-precipitable counts, were immunoprecipitated overnight by anti-GRF
antisera or precipitated with glutathione-Sepharose beads (Pharmacia). The pellets were washed twice with nondenaturing lysis buffer, twice
with HNTG (20 mM HEPES [pH 7.0], 500 mM NaCl, 0.1% Triton, 10%
glycerol), and solubilized in Laemmli sample buffer. After separation
by 6 to 13% gradient SDS-PAGE, proteins were detected by
autoradiography. For transfected 293T cells, immunoprecipitation followed by immunoblotting was used for the analysis of GRF oligomers. For analysis of more than one protein, blots were stripped according to
the manufacturer's instructions (Amersham) and reprobed with the
appropriate antibody.
Whole brains from several 2-day-old Sprague-Dawley rats (Taconic Farms)
were homogenized in ice-cold extraction buffer (20
mM Tris-HCl [pH
8.0], 1% Nonidet P-40 [NP-40], 10 nM EGTA, 5 mM
MgCl
2,
20 mM

-glycerophosphate, 1 mM Na
3 VO
2, 1 mM
dithiothreitol
[DTT], 1 mM phenylmethylsulfonyl fluoride [PMSF], 10 µg of leupeptin
per ml, 10 µg of aprotinin per ml) by 10 strokes
with a glass
homogenizer. The crude lysates were first cleared by
centrifugation
at 12,000 ×
g for 15 min at 4°C and
then centrifuged at 100,000
×
g for 30 min at 4°C.
The supernatants were collected, and the
protein concentration was
estimated by the BCA kit (Pierce). For
the detection of complex
formation between GRF1 and GRF2 in the
brain extract, antibodies
specific for GRF1 (
9), rodent GRF2
(Transduction
Laboratories), or human GRF2 as described, which
in preliminary
experiments were found not to recognize the heterologous
GRF isoform,
were used to obtain high sensitivity and specificity.
In the assay, the
4 to 5 mg of extract was first precleared with
protein A-Sepharose by
rotating for 1 h at 4°C. One-quarter of
the extract was then
used as a control, i.e., anti-GRF1 immunoprecipitation
followed by
anti-GRF1 immunoblotting. The remaining three-quarters
of the extract
was immunoprecipitated with the anti-GRF2 antibodies,
followed by
immunoblotting with anti-GRF1. The immunocomplexes
were washed twice
with extraction buffer, twice with HNTG containing
0.5 M NaCl, and
twice with low-salt HNTG (containing 150 mM NaCl
instead of 500 mM).
The beads were then resuspended with sample
loading buffer, separated
by gradient SDS-PAGE, and immunoblotted
as described
above.
Cell culture, transfection, and focus formation assays.
NIH
3T3 (clone 7), COS-7, and HEK 293T (293T) cells were maintained in DMEM
supplemented with 10% FBS at 37°C in a humidified 5%
CO2 atmosphere. NIH 3T3 cells were transfected with 0.4 µg of pEFP vector encoding wild-type or mutant GRF1 or pGV16-MyrSos1 (41) with calcium precipitation as described previously
(53). Foci were counted after 14 days.
Calmodulin immunocomplex formation with GRF1 and GRF2.
pEFP
vectors encoding GRF1 or GRF2 were transiently transfected into 293T
cells by using Lipofectamine Plus (Life Technologies) according to the
manufacturer's instructions and analyzed 48 h after transfection.
The day following transfection, cells were serum deprived for 18 to
20 h and stimulated with 5 µM of ionomycin (Sigma) at 37°C for
5 min. Cells were solubilized by nondenaturing lysis buffer (20 mM Tris
[pH 7.4], 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EDTA, 10 mM Na3VO4, 10 mM NaF, 1 mM PMSF, aprotinin [10
µg/ml], leupeptin [10 µg/ml]). Equal amounts of protein from the
cleared cell lysates were immunoprecipitated with anti-GRF1- or
anti-GRF2-specific antiserum for 2 h on ice. Then, 50 µl of
protein A-Sepharose slurry was added and rotated at 4°C for at least
3 h. Immunocomplexes were then washed twice with nondenaturing
lysis buffer and twice with HNTG and then denatured in Laemmli sample
buffer. After resolution by 6 to 13% gradient SDS-PAGE and transfer to
PVDF membranes, immunoblotting was performed to detect the expression
of GRF1 and GRF2 by using cognate anti-serum at a 1:1,000 dilution.
Calmodulin that had coimmunoprecipitated with the anti-GRF sera was
examined by using anti-calmodulin monoclonal antibody (UBI) at a
1:2,000 dilution. For each blot, horseradish peroxidase-conjugated
anti-rabbit or anti-mouse immunoglobulin G (Amersham) was used for the
second reaction at a 1:10,000 dilution. Immunocomplexes were visualized
by enhanced chemiluminescence with an ECL Kit from Amersham.
Erk and Raf-1 kinase assays.
NIH 3T3 cells or 293T cells
were transiently cotransfected with pcDNA3-HA-ERK2 (a gift from Silvio
Gutkind, National Institutes of Health) and pEFP-GRF1, pEFP-GRF1L263Q,
or empty vector, and assayed 2 days after transfection. Transfected
cells that had been deprived of serum for 16 to 20 h were either
left untreated or were treated with ionomycin (5 µM) for 5 min. For
MAP kinase assays, cells were lysed with radioimmunoprecipitation assay
buffer (25 mM Tris-HCl [pH 7.5], 300 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 1% Triton X-100, 0.5%
NaDOC, 0.1% SDS, 20 mM
-glycerophosphate, 1 mM sodium
orthovanadate, aprotinin [10 µg/ml], 1 mM PMSF, leupeptin [10
µg/ml]). Protein concentrations were determined by using the BCA kit
(Pierce). Equal amounts of protein (100 µg) from cell extracts were
immunoprecipitated with anti-HA monoclonal antibody (Babco). After the
complexes were washed twice with PBS containing 1% NP-40 and 2 mM
Na3VO4, once with buffer 2 (100 mM Tris, [pH 7.5], 0.5 M LiCl2), and once with reaction buffer (12.5 mM
MOPS [morpholinepropanesulfonic acid; pH 7.4], 12.5 mM
-glycerophosphate, 7.5 mM MgCl2, 0.5 mM EGTA, 0.5 mM
sodium orthovanadate, 0.5 mM NaF), the immunocomplexes were incubated
with 50 µl of reaction buffer containing 20 µM ATP, 1 µCi of
[
-32P]ATP (NEN-Dupont), and 2 µg of myelin basic
protein (MBP; Upstate Biotechnology, Inc.). After incubation for 20 min
at 30°C, kinase reactions were terminated by the addition of 2×
Laemmli sample buffer. The samples were then resolved by SDS-PAGE, and
the phosphorylated MBP was visualized by autoradiography. For
quantitation, dried gels were exposed on Phosphor Screens, and signals
were captured on a Molecular Dynamics PhosphorImager and analyzed by
using ImageQuant software. Control for equal loading was done by
examining exogenous HA-ERK2 proteins by immunoblotting with
anti-hemagglutinin (HA) antibody.
For the Raf1 kinase assay, 293T cells were transiently transfected with
pEFP-GRF1, pEFP-GRF1L263Q, or empty vector, together
with 0.4 µg of
c-Raf-1. At 24 h posttransfection, the cells were
serum starved
overnight and then stimulated with or without 5
µM ionomycin for 5 min at 37°C. The cells were washed twice with
ice-cold PBS and lysed
by using Gold Lysis Buffer (GLB) containing
20 mM Tris-HCl [pH 7.9],
137 mM NaCl, 5 mM EDTA, 10% glycerol,
1% Triton X-100, 1 mM EGTA, 10 mM NaF, 1 mM sodium pyrophosphate,
100 µM

-glycerophosphate, 1 mM
leupeptin, aprotinin [10 µg/ml],
and 1 mM PMSF. Lysates from 293T
cells (180 µg) were immunoprecipitated
with 2 µg of Raf-1 antibody
(Santa Cruz). The immunocomplexes
were washed twice with GLB; once with
buffer containing 10 mM
HEPES [pH 7.4], 100 mM NaCl, 20 µg of
aprotinin per ml, and 0.5%
NP-40; and finally with reaction buffer (20 mM Tris [pH 7.4],
20 mM NaCl, 1 mM DTT, 10 mM MgCl
2, 1 mM
MnCl
2). The complexes
were then incubated in 40 µl of
reaction buffer supplemented with
25 µM PD98059 (RBI), an MEK
inhibitor to prevent autophosphorylation,
10 µM ATP, 2 µCi of
[

-
32P]ATP, and 100 ng of MEK for 30 min at 30°C.
Reactions were stopped
and processed as described for the MAP kinase
assay.
In vivo analysis of GTP-Ras.
In vivo analysis of GTP-Ras was
performed as described previously, with minor modifications
(54). Subconfluent NIH 3T3 or 293T cells were transiently
transfected with pEFPGRF1, pEFPGRF1L263Q, or empty vector for 24 h, deprived of serum for 16 hours, metabolically labeled with
[32P]orthophosphate for 6 h, and stimulated where
indicated with 5 µM ionomycin or 20 nM epidermal growth factor (EGF)
for 5 min. Cells were rinsed with PBS and lysed in 20 mM Tris-HCl (pH
7.4)-100 mM NaCl-20 mM MgCl2-1% NP-40-0.5% sodium
deoxycholate. Ras protein was immunoprecipitated with monoclonal
antibody Y13-259 (25), followed with thin-layer
chromatography on PEI cellulose plates in 1.3 M LiCl, and analyzed with
an AMBIS Radioanalytic Imaging apparatus. Determination of the
percentage of GTP (GTP/[GTP + GDP]) bound to Ras was normalized
for the moles of phosphate.
 |
RESULTS |
Two-hybrid screen identifies a human cDNA insert that encodes the
IQ motif and Dbl homology domain of human GRF2.
To identify
proteins that interact with the DH domain of GRF1, we employed the
yeast two-hybrid system (22) as modified by Durfee et al.
(12). As bait for the two-hybrid screen, we used a
selectable plasmid, termed pAS1GRFdbl, which encoded a fusion between
the Gal4 DNA-binding domain and the DH domain plus flanking regions of
mouse (m) GRF1 (amino acids 221 to 497; BD-mGRF1 in Fig. 1).
The yeast reporter strain Y190 was cotransformed with pAS1GRFdbl
and a selectable human brain cDNA library (Clontech). To select for
cells that received a plasmid of each type and also activated the
resident His plasmid in the yeast strain, cells were plated on
synthetic minimal medium lacking His, Leu, and Trp but containing 25 mM
3-aminotriazole (3-AT) and then incubated at 30°C for 5 to 7 days.
The His+ colonies were then screened for activation of
-galactosidase gene activity in the yeast cells, an activity which
should also depend on a two-hybrid interaction. Of 2.2 × 106 yeast transformants, 180 grew in the absence of
histidine, and 6 of these transformants were positive for
-galactosidase activity as determined by filter assay (not shown).
The inserts from these six plasmids were digested by several
restriction enzymes, including RsaI and TaqI.
This yielded identical patterns for each of the six inserts (not
shown). These plasmids were therefore considered identical, and one,
designated pGAD10.56, was chosen for further analysis.
To verify the specificity of the interaction between pGAD10.56 and the
mGRF1 bait, pAS1GRFdbl, we cotransformed the yeast
reporter strain with
pGAD10.56 and a number of different plasmid
baits expressing various
GAL4-binding domain fusion proteins,
including a fusion encoding mGRF1
amino acids 464 to 604 (Table
1). Among these
baits, only cotransformation of pGAD10.56 with
pAS1GRFdbl yielded yeast
cells that could grow on minimal medium
in the presence of 3-AT and
express

-galactosidase activity.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Specificity of the interaction of the DH domain of hGRF2
[AD-hGRF2(176-474)] with the DH domain of mGRF1
[BD-mGRF1(221-497)] in the yeast
two-hybrid systema
|
|
Having determined that the interaction was specific, we obtained the
sequence of the human cDNA insert of plasmid pGAD10.56
and found a
partial cDNA predicted to encode a polypeptide of
299 amino acids,
which was then compared against a protein database
by using the basic
local alignment sequence tool (
1). Unexpectedly,
a strong
homology was found to the GRF DH domain and IQ motif,
with the closest
homology being to mGRF2 (
17) [AD-hGRF2(176-474)
in Fig.
1]. Comparison of the polypeptide sequence encoded by
pGAD10.56 with
the corresponding region of mGRF2 showed 97% identity,
versus 81%
identity with mGRF1 (Fig.
2). This result
strongly
suggested that the human cDNA insert of pGAD10.56 corresponds
to a portion of human (h) GRF2.

View larger version (114K):
[in this window]
[in a new window]
|
FIG. 2.
Comparison of the sequences of mouse (m) and human (h)
forms of Ras-GRF1 (GRF1) and Ras-GRF2 (GRF2). Alignment is given in
comparison with hRas-GRF2 (hGRF2). Going from the N terminus to the C
terminus, the boxes indicate the PH, IQ, DH-PH, and the Ras catalytic
domains, respectively (see Fig. 1). An asterisk indicates sequence
identity with respect to hRas-GRF2; a dash indicates a deletion. The
underlined sequence of mRas-GRF1 (mGRF1) corresponds to the bait used
in the two-hybrid screen (residues 221 to 497 of mGRF1). The underlined
sequence of hGRF2 corresponds to the insert of clone pGAD10.56, the
sequence trapped in the two-hybrid screen (residues 176 to 474 of
hRas-GRF2). The GenBank accession numbers are as follows: L20899
(mGRF1), U67326 (mGRF2), L26584 (hGRF1), and AF023130 (hGRF2). The
following regions are not highly conserved between GRF1 and GRF2: (i)
the most N-terminal PH domain (and to a lesser extent the PH domain C
terminal to the DH domain); (ii) the region corresponding to residues
Ser-180-Glu-200 of hGRF2, in which only 6 of 21 residues are identical
between mGRF1 and hGRF2 (this region was used to generate a
GRF2-specific peptide antibody); and (iii) the region corresponding to
residues Thr761-Pro-878 of hGRF2, in which only 20 of 118 residues are
identical between hGRF2 and hGRF1. This region, which is much shorter
in mGRF2, was chosen to generate cDNA probes for Northern analysis of
human tissues.
|
|
Cloning of the full-length cDNA encoding hGRF2.
To confirm
that the cDNA was part of the putative hGRF2, the full-length human
cDNA was isolated by 5' rapid amplification of cDNA ends (RACE) and 3'
RACE, performed with a human hippocampal cDNA (Clontech) as a template.
The complete open reading frame of the cDNA was found to consist of
3,711 nucleotides encoding a polypeptide of 1237 amino acids, with a
predicted molecular mass of 136 kDa (Fig. 2). Comparing the polypeptide
sequence with that of mGRF2 confirmed its identity as hGRF2. The
overall sequence identity of the two proteins is 90%, versus a 64%
identity with mGRF1. Northern analysis of human tissues confirmed a
previous report by Fam et al. (17) that GRF2 is more widely
expressed than GRF1, and we also found that mRNA for GRF2 was most
abundant in the brain, followed by heart tissue and several other
tissues such as lung, pancreas, and kidney tissues (data not shown). By Western blot analysis, full-length hGRF2 protein was detected in brain
and lung tissue (not shown).
Mapping the interacting regions.
The pGAD10.56 prey, which
consists of hGRF2 amino acids 176 to 474, contains the IQ and DH
domains, while the pASGRFdbl mGRF1 bait consists of mGRF1 amino acids
221 to 497, which represent the DH domain and the N-terminal portion of
the adjacent PH domain (Fig. 1). To determine whether sequences other
than the respective DH domains were required for the two-hybrid
activity, the IQ domain (amino acids 176 to 233) was deleted from the
hGRF2 prey [AD-hGRF2(234-474) in Fig. 1] and the PH domain sequences
(amino acids 461 to 497) were deleted from the mGRF1 bait
[BD-mGRF1(221-460)], and their functions were examined in the
two-hybrid assay. Deletion of the IQ domain from hGRF2
[AD-hGRF2(234-474)] did not prevent the interaction with the mGRF1
bait, while removal of the N-terminal part of the PH domain from the
mGRF1 bait [BD-mGRF1(221-460)] resulted in
-galactosidase
activity that was more than twofold higher than that of the wild type
(Table 2). These results demonstrate that the
interaction, as measured in the two-hybrid assay, requires only the DH
domain of each peptide.
To confirm the essential nature of the mGRF1 DH domain for the
interaction, substitution mutations were introduced in either
of two
regions within the mGRF1 DH domain. Both regions are highly
conserved
between DH domains of various Dbl-related proteins (
3,
46).
In one case, a point substitution L263Q was introduced
into the most
N-terminally located structurally conserved region
of the DH domain
[BD-mGRF1(221-497)L263Q in Fig.
1]. In the other,
a cluster mutation
was introduced in the third structurally conserved
region
(
3), replacing residues (394)LTLHELL(400) with residues
(394)IIIRDII(400) [BD-mGRF1(221-497)IIIRDII in Fig.
1]. In oncogenic
Dbl, an analogous mutation cluster greatly reduces its in vitro
exchange activity as well as its transforming activity on NIH
3T3 cells
(
28), and this cluster mutation in rat GRF1 attenuated
its
capacity to respond to the ionomycin-dependent activation
of Erk
(
24). However, engineering the DH cluster mutation in
the
mGRF1 bait did not prevent its interaction with the hGRF2
prey (Table
2). Quantitative analysis of the

-galactosidase
assay revealed that,
compared with the wild-type mGRF1 bait, the
interaction between the
cluster mutant and the hGRF2 IQ-DH prey
was only marginally lower. By
contrast, introduction of the L263Q
substitution in the mGRF1 prey
abolished the two-hybrid interaction
(Table
2).
Oligomerization occurs in mammalian cells.
We wished to
determine whether the interaction between the DH domains of GRF1 and
GRF2 DH detected by the yeast two-hybrid assay also occurs with the
full-length proteins in mammalian cells, whether hetero-oligomerization
occurs between GRF1 and other proteins that contain DH regions, and
whether GRF1 and GRF2 form oligomers with themselves. Initially, we
transferred the hGRF2 coding sequences from the pGAD10.56 prey, tagged
with a FLAG epitope, to a mammalian expression vector and cotransfected
this construct with full-length GST-mGRF1 or GST alone into COS-7
cells. Immunoprecipitation with antibodies against GST showed a
specific coprecipitation of the GRF2 construct, demonstrating that the
interaction identified in the yeast two-hybrid assay could be detected
as complex formation in mammalian cells (data not shown). These results
led us to determine whether the full-length GRF1 and GRF2 proteins form
homo-oligomers and/or hetero-oligomers. To carry out these analyses,
additional plasmids were constructed for full-length mGRF1 containing
either the L263Q mutation or the DH cluster mutation, full-length wild type hGRF2, and full-length hGRF2 fused to GST (GST-GRF2).
Oligomer formation with full-length proteins was first examined in NIH
3T3 cells, which were transiently cotransfected with
(i) GST-GRF1 and
(ii) wild-type mGRF1, the L263Q mGRF1 mutant,
or wild-type GRF2 (Fig.
3A). Metabolically labeled NIH 3T3 lysates
were precipitated with glutathione-Sepharose beads, which recognize
GST
but not GRF (Fig.
3A, lane 7). As expected, GST-GRF1 signals
were
present in the precipitates from GST-GRF1 transfectants (Fig.
3A, lanes
4 to 6). In addition to GST-GRF1, the precipitates from
the cells
cotransfected with GST-GRF1 and wild-type GRF1 (lane
4) or wild-type
GRF2 (lane 6) contained GRF1 and GRF2, respectively
(note that GRF1
[lane 4] and GRF1 immunoprecipitates [lane 1]
migrated slightly
more slowly than GRF2 [lane 6] and GRF2 immunoprecipitates
[lane
3]). These results indicated that complexes were formed
between
GST-GRF1 and wild-type GRF1 or wild-type GRF2. By contrast,
precipitates from cells cotransfected with GST-GRF1 and the L263Q
GRF1
mutant contained almost no mutant protein (lane 5), although
control
immunoprecipitations with GRF1 and GRF2 antibodies indicated
the
transfectants contained similar amounts of wild-type or mutant
protein
(Fig.
3A, lanes 1 to 3). Similar results were also obtained
in COS-7
cells (data not shown).

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 3.
Formation of GRF1 and GRF2 oligomers in mammalian cells.
(A) GRF oligomerization occurs in NIH 3T3 cells between GST-GRF1 and
wild-type GRF1 or wild-type GRF2, but it is deficient between GST-GRF1
and the L263Q GRF1 mutant. Metabolically labeled NIH 3T3 cells
transiently expressed mGRF1, mGRF1L263Q, and hGRF2, with or without
GST-mGRF1 or GST, as indicated. Cell lysates were immunoprecipitated
with antisera to GRF1 (lanes 1 and 2), GRF2 (lane 3) or precipitated
with glutathione-Sepharose (GS) beads (lanes 4 to 7). The arrows
indicate the location of GRF1 (lanes 4 and 5) or GRF2 (lane 6)
coprecipitated with GST-GRF1 (lanes 4 to 6) and the location of GST
(lane 7). (B) Wild-type GRF1 and the DH cluster mutant form oligomers
in 293T cells, but oligomerization is deficient with the L263Q mutant.
Transiently transfected cells expressing wild-type (lanes 1, 2, 4, and
6) or mutant GRF1 (L263Q in lanes 3 and 5; cluster mutant [GRF1*] in
lane 7), with or without coexpression of GST-GRF1, were precipitated by
glutathione-Sepharose (GS) beads or GRF antibodies as indicated,
followed by anti-GRF1 blotting. The designated oligomerized proteins
are marked with arrows. (C) Oligomerization in 293T cells. In lanes 1 to 3, lysates from cells expressing GRF2 with or without coexpression
of GST-GRF1 or GST were immunoprecipitated and blotted with anti-GRF2.
In lanes 4 and 5, lysates from cells coexpressing GST-GRF2 and GRF1 or
GRF2 were precipitated with glutathione-Sepharose (GS) beads followed
by anti-GRF2 blotting. In the bottom panels, the anti-GRF2 blots were
(incompletely) stripped and were reprobed with GRF1 antibodies. The
designated oligomerized proteins are marked with arrows. (D) A rat
brain extract (RBE) contains GRF1-GRF2 oligomers. Lanes: 1 and 2, extracts from 293T cells expressing GRF2 and GRF1, respectively,
Western blotted with anti-GRF2 antibodies; 3 and 4, rat brain extracts
immunoprecipitated with anti-GRF1 and anti-GRF2, respectively; 5, 293T
cells coexpressing GRF1 and GRF2 immunoprecipitated with anti-GRF2
antibodies; 6 and 7, 293T cells expressing GRF1 immunoprecipitated with
anti-GRF1 or anti-GRF2 antibodies, respectively.
|
|
GRF oligomerization was also analyzed in unlabeled transiently
transfected 293T cells, by precipitation with
glutathione-Sepharose
beads, followed by Western blotting
with antibodies specific for
GRF1 or GRF2 (Fig.
3B and C, lanes 3 to
5), or by immunoprecipitation
and Western blotting (Fig.
3C, lanes 1 and 2). Lysates from 293T
cells cotransfected with GST-GRF1 and
wild-type GRF1 formed a
readily detectable complex (Fig.
3B, lane 2).
This complex required
GRF1 in the GST fusion, as the association did
not occur in cells
cotransfected with GST and wild-type GRF1 (lane 1).
As in the
NIH 3T3 cells, the L263Q GRF1 mutant was deficient in its
association
with GST-GRF1 (lane 3), although the cells expressed
similar levels
of wild-type or L263Q mutant protein (lanes 4 and 5). In
contrast
to the impaired complex formation seen with the L263Q GRF1
mutant,
the efficiency of complex formation between GST-GRF1 and the DH
cluster mutant (designated GRF1* in lane 7) was similar to that
between
the wild type and GST-GRF1 (lane 6). Conversely, specific
oligomerization was found between GST-GRF2 and either wild-type
GRF1 or
wild-type GRF2 (Fig.
3C, lanes 3 to 5). Complex formation
between
GST-GRF1 and GRF2 was also shown by immunoprecipitation
with GRF2
antibodies and Western blotting with GRF1 antibodies
(Fig.
3C, lanes 1 and 2; note that the GRF2 blot for these lanes
was incompletely
stripped). In addition, complex formation between
wild-type GRF1 and
wild-type GRF2 was also shown for cells expressing
both proteins (Fig.
3D, lane
5).
Taken together, the data indicate that hetero-oligomers form between
GRF1 and GRF2 in mammalian cells and that homo-oligomers
composed of
GRF1 or of GRF2 can also form. As in the yeast two-hybrid
assay,
introduction of the DH cluster mutation did not interfere
with
oligomerization, while introduction of the L263Q mutation
led to a
protein that was deficient in oligomer formation. It
should also be
noted that the oligomerization assays underestimate
the overall
efficiency of oligomerization because they detect
only those oligomers
that form between proteins that can be distinguished
by virtue of their
distinct size (as between GST-GRF1 and GRF1
in Fig.
3A and B) or their
distinct antigenic properties (as between
GRF1 and GRF2 in Fig.
3C).
The assays of the cotransfected cells
do not identify the two species
of homo-oligomers that must also
be forming between molecules of the
same protein species, such
as GRF1 homo-oligomers and GRF2
homo-oligomers in cells cotransfected
with plasmids encoding these two
proteins.
To determine whether complex formation might occur between GRF1 and
less closely related proteins that also contain DH domains,
GRF1 was
cotransfected with c-Dbl or with Sos1, each of which
contain a Dbl
domain. However, under conditions where GRF1 formed
oligomers with
itself or with GRF2, no complexes were seen between
GRF1 and c-Dbl or
Sos1 (data not shown). Thus, the ability to
form such oligomers appears
to be restricted to GRF1 and GRF2,
whose DH domains are more closely
related to each other than to
the DH domains of c-Dbl or
Sos.
Rat brain extracts contain GRF1-GRF2 oligomers.
The
above-described studies indicated that forced expression of GRF1 and
GRF2 led to oligomer formation in cultured cells. To determine whether
oligomerization between GRF1 and GRF2 occurs in a physiologic context,
a whole-brain extract made from postnatal rats was used to examine this
possibility, as Northern blots from various areas of human brains
indicated that GRF1 and GRF2 mRNA were expressed in most regions of the
brain (data not shown). When the rat brain extract was
immunoprecipitated with anti-GRF2 antibodies, GRF1 was also
coprecipitated, as demonstrated by Western blotting of the
immunoprecipitate with anti-GRF1 antibodies (Fig. 3D, lane 4). Several
controls were run with this assay to confirm the specificity of the
results. Immunoprecipitation with the anti-GRF2 antibodies of
transfectants expressing GRF1 did not precipitate GRF1 detectable by
Western blotting with the anti-GRF1 antibodies (lane 7), despite the
presence of GRF1 in the transfectants (lane 6). In addition, the
anti-GRF2 antibodies did not detect GRF1 in a Western blot of extracts
from cells expressing GRF1 (lane 2), although the antibodies could
readily detect expressed GRF2 (lane 1). We conclude that GRF
oligomerization occurs physiologically in at least some parts of the brain.
Biological activity in NIH 3T3 cells.
Full-length mGRF1 has
been reported previously to induce focus formation in NIH 3T3 cells
(9). To determine the effect of the L263Q and DH cluster
mutations on this activity, NIH 3T3 cells were transfected with the
wild-type gene, the L263Q mutant, or the DH cluster mutant (Fig.
4). The transforming activity of the DH
cluster mutant was about 1 order of magnitude lower than that of wild
type, while the L263Q mutant was repeatedly transformation defective,
although transient transfection indicated that the wild-type and mutant
genes expressed similar levels of protein in the cells (Fig.
5A; data shown for wild type and the L263Q mutant). Since the DH cluster mutant formed oligomers with an efficiency similar to that of wild type (Fig. 3B, lanes 6 and 7),
whereas the L263Q mutant was deficient in this activity (Fig. 3A, lane
5, and Fig. 3B, lane 3), the cell transformation results support the
possibility that GRF oligomerization contributes to the biological
activity of the protein. Consistent with their relative transforming
activity, the Erk activity in transiently transfected NIH 3T3 cells was
highest for the wild-type GRF1 (5.9 arbitrary units versus 1.0 for the
vector control), followed by the cluster mutant (4.1 U) and the L263Q
mutant (3.4 U) (Fig. 5A; primary data not shown for the cluster
mutant). In addition, wild-type GRF1 induced a higher level of GTP-Ras
than the L263Q mutant in transiently transfected cells (Fig. 5B).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 4.
Focal transforming activity of GRF1. NIH 3T3 cells
transfected with the indicated GRF1 constructs. The data shown
represent the mean of four separate experiments (three readings per
experiment). Each bar shows the transforming activity and the standard
error.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 5.
Erk and GTP-Ras in NIH 3T3 cells. Assays were carried
out 2 days after transfection of NIH 3T3 cells with the indicated GRF1
plasmid. (A) Erk activity in NIH 3T3 cells. Cells were transiently
cotransfected with empty vector, wild-type GRF1 (GRF1), or the L263Q
GFR1 mutant (L263Q), along with HA-ERK2. In the upper portion of the
panel, the basal Erk activity was determined by precipitating lysates
with HA antibody, followed by kinase assay of the immune complex with
MBP as the substrate. In the middle portion of the panel, the presence
of GRF1 or the mutant was verified by Western blotting of the
immunoprecipitates. In the lower portion of the panel, the blots were
stripped and probed with the HA antibody to verify the equal expression
of HA-Erk2. The arrows show the location of MBP, GRF1, and HA-Erk in
the upper, middle, and lower portions, respectively. (B) In vivo
measurement of GTP and GDP bound to Ras in transiently transfected NIH
3T3 cells. Cells were metabolically labeled with
[32P]orthophosphate, extracts were immunoprecipitated
with a Ras-specific monoclonal antibody, and the percentage of GTP-Ras
was determined by thin-layer chromatography as described in Materials
and Methods.
|
|
Ionomycin-dependent stimulation of Erk activity is not associated
with an increase in GTP-Ras.
As noted above, treatment of 293T
cells expressing rat GRF1 with a calcium ionophore, ionomycin, has been
shown to increase the Erk activity in conjunction with calmodulin
binding. We confirmed these results for wild-type mouse GRF1 protein in
transiently transfected 293T cells (Fig. 6).
In the absence of ionomycin treatment, the basal Erk2 activity in 293T
cells transfected with wild-type GRF1 was, as expected, higher than in
cells transfected with the empty vector, and treatment with ionomycin
for 5 min led to a severalfold increase in Erk2 activity (Fig. 6B and
C), as well as in calmodulin binding to GRF1 (Fig. 6A, lanes 1 and 2).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 6.
Calmodulin binding and ERK activity in 293T cells
expressing wild-type GRF1 and L263Q mutant. (A) 293T cells were
transiently transfected with wild-type GRF1 or the L263Q mutant, serum
starved overnight, and either left untreated ( ) or treated with
ionomycin for 5 min (+). Cell lysates were immunoprecipitated with GRF1
antibodies and blotted with GRF1 antibodies (top portion of the panel)
or with a calmodulin antibody (bottom portion of panel). Lane 4 contains only input calmodulin marker. (B) Basal and ionomycin-induced
Erk activation in 293T cells transfected with GRF1. Cells were
transiently transfected with vector, wild-type GRF1, or the L263Q
mutant along with HA-ERK2, serum starved overnight, and either left
untreated ( ) or treated with ionomycin for 5 min (+). The exogenous
ERK activity was determined as described in the text. The cells were
processed and analyzed as described for panel A. (C) Quantitation of
ERK activity. The amount of radioactivity present in phosphorylated MBP
was quantitated with a phosphorimager. The activity of exogenous Erk
was based on the mean of two experiments.
|
|
Another feature of rat GRF1 is that calcium-dependent Erk activation is
markedly reduced in the mutant carrying the DH cluster
mutations, as
well as for mutants affecting the CC region or either
of the PH
domains, although these mutants bound calmodulin in
an
ionomycin-dependent manner (
6,
24). We confirmed that
this
activity was attenuated with the DH cluster mutant (data
not shown) and
determined whether the L263Q mutant would behave
similarly. Compared
with cells transfected with wild-type mGRF1,
ionomycin treatment of
cells transfected with the L263Q mutant
induced an attenuated increase
in Erk activity (Fig.
6B and C),
although calmodulin bound to the
mutant protein (Fig.
6A, lane
3). Thus, these results are analogous to
those reported for rat
GRF1
mutants.
We also examined whether the level of GTP-Ras in the 293T cells would
correlate with Erk activity (Fig.
7A). As
expected,
transient transfection of wild-type GRF1, in the absence of
ionomycin,
led to a substantial increase in the basal level of GTP-Ras
compared
to control cells transfected with the empty vector. To our
surprise,
however, there was no additional increase in GTP-Ras when the
GRF1-expressing cells were treated with ionomycin, despite the
ability
of this treatment to stimulate the substantial increase
in Erk activity
noted above. Cells transfected with the L263Q
mutant also showed an
increase in basal GTP-Ras, although it was
less than that seen with the
wild-type mGRF1, and the GTP-Ras
levels did not increase further with
ionomycin treatment. To rule
out the possibility that the lack of
GTP-Ras in response to ionomycin
might be secondary to an inability of
the transfected cells to
increase further their level of GTP-Ras, cells
were treated with
EGF or with ionomycin. Although EGF treatment of
GRF1-expressing
cells demonstrated a further increase in GTP-Ras,
ionomycin actually
led to a small decrease in GTP-Ras in the same
experiment (Fig.
7B).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 7.
GTP-Ras in 293T cells expressing wild-type GRF1 and
L263Q mutant. Cells were transiently transfected with the indicated
GRF1 gene. Cultures were serum starved and metabolically labeled with
[32P]orthophopshate, cells were treated with 5 µM
ionomycin or 20 nM EGF for 5 min, extracts were immunoprecipitated with
a Ras-specific monoclonal antibody, and the percentage of GTP-Ras was
determined by thin-layer chromatography as described in Materials and
Methods. Results in panel A represent the average of two experiments,
while the results in panel B are from a single experiment.
|
|
Ionomycin induces increased Raf activity.
The failure of
ionomycin to increase GTP-Ras in the GRF1-expressing cells implied that
another mechanism would account for the ionomycin-dependent increase in
Erk. Three features of Raf led us to examine this serine-threonine
kinase as a possible downstream target for the ionomycin-dependent
increase in Erk: Raf is part of the Erk pathway, Raf lies immediately
downstream from Ras, and Raf is only partially activated by Ras
(reviewed in reference 38). 293T cells were
transiently cotransfected with GRF1 and c-Raf, treated with ionomycin,
and extracts were immunoprecipitated with anti-Raf antibodies. The
kinase activity of the immunoprecipitates was then analyzed by the in
vitro phosphorylation of MEK, an authentic Raf substrate located
between Raf and Erk (Fig. 8). Consistent with
the basal increase in GTP-Ras in cells expressing wild-type GRF1, the
basal level of Raf kinase activity in these cells was also increased
compared to extracts of cells transfected with the empty vector.
Ionomycin treatment of the transfected cells induced a further increase
in Raf activity over this already-elevated basal activity. This
ionomycin-induced GRF1-dependent increase in Raf kinase probably
occurred by a Ras-independent mechanism, given the lack of increase in
GTP-Ras seen with ionomycin treatment of GRF1-expressing cells (Fig.
7).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 8.
GRF1 increased Raf activity in response to ionomycin.
Transiently transfected 293T cells were treated with or without
ionomycin after serum starvation as in Fig. 6. Cell lysates were
immunoprecipitated with Raf antibodies, and the immunocomplexes were
assayed for in vitro kinase activity by using MEK-1 as a substrate
(upper part of panel). The amount of radioactivity present in
phosphorylated MEK-1 was determined with a phosphoimager, and the fold
increase, compared with the untreated vector control, is shown
underneath the upper part of the panel. The expression of Raf and GRF1
was confirmed by immunoblotting, as shown in the middle and bottom
panels, respectively.
|
|
To confirm the dependence of this response on wild-type GRF1, the Raf
activity was also determined for companion cells cotransfected
with the
L263Q mutant and c-Raf (Fig.
8). The results obtained
in the Raf kinase
assay correlated with those observed with this
mutant in the Erk assays
in that ionomycin treatment induced a
smaller increase in Raf kinase
than was seen with wild-type
GRF1.
 |
DISCUSSION |
In this study, we report two unexpected observations about the
Ras-specific exchange factor GRF: (i) GRF1 and GRF2 can form homo- and
hetero-oligomers, via their respective DH domains, which represents a
hitherto-unreported function for a DH domain; and (ii) the
ionomycin-induced Erk activity of GRF1 occurs via at least two
cooperative GRF1-dependent signaling pathways that converge to activate
Raf. In 293T cells under the conditions examined, one pathway is a
constitutive GRF1-dependent increase in GTP-Ras, which occurs in the
absence of ionomycin. The other pathway is a further GRF1-dependent
increase in Raf activity, which is induced by ionomycin. This latter
activation occurs via a Ras-independent mechanism in that it is not
associated with a further increase in GTP-Ras.
Homo- and hetero-oligomerization of GRF1 and GRF2.
Dimerization via the DH domains was seen initially in a yeast
two-hybrid screen developed to identify proteins in a human brain cDNA
library that might interact with the mGRF1 DH domain. This screen
identified, in the brain library, an encoded polypeptide which turned
out to consist of the IQ motif and the DH domain from hGRF2. Deletion
analysis of the hGRF2 polypeptide indicated that the IQ motif was
dispensable for the interaction, as were the few non-DH domain amino
acids present in the mGRF1 bait. Mutation of a highly conserved leucine
residue to glutamine (L263Q) in mGRF1 inactivated the interaction with
hGRF2. The leucine residue forms part of a structurally conserved
N-terminal region of the DH domain (3, 46). By contrast, a
cluster of mutations in a C-terminal region of the DH domain did not
abolish the interaction. Taken together, the above results implied that
the mGRF1 DH domain was capable of interacting with the hGRF2 DH
domain, and L263 in mGRF1 was required for this interaction.
When the examination was extended to mammalian cells, the results
confirmed that a complex was formed between GRF1 and GRF2
in a rat
brain extract or when the full-length proteins were coexpressed
in
cells and, further, that GRF1 and GRF2 can each form homo-oligomers.
The analysis also established that homo-oligomer formation for
GRF1 is
impaired by the L263Q mutation (the analogous mutation
was not
introduced into GRF2) but not by the DH cluster mutation.
Complex
formation between the DH domains of GRF1 and GRF2 appears
to be
relatively specific, since complexes were not detected between
GRF1 and
two other proteins that contain DH domains, Sos1 and
c-Dbl. It may be
relevant that the DH domains in Sos1 and c-Dbl
share less than 30%
identity with the GRF1 DH domain, while the
DH domains of GRF1 and GRF2
are more than 80% identical. It is
likely that the oligomerization of
GRF1 and GRF2 represents a
direct interaction between DH domains that
are identical (in the
case of homo-oligomerization) or very closely
related (in the
case of hetero-oligomerization), but it remains
possible that
the complex formation identified here might depend on an
additional
unidentified molecule. Such a putative molecule would need
to
be conserved between yeasts and mammals, given the similarity
of the
results in both systems. What we are designating as "oligomers"
probably represent dimers, but our data do not rule out the possibility
of
multimers.
Oligomerization has also been reported for the yeast homolog of GRF,
Cdc25p, both with itself and with Sdc25p, which is a
closely related
exchange factor (
8). In Cdc25p, the oligomerization
domain
was localized to its C-terminal portion, which contains
the Ras
catalytic domain and the signal responsible for membrane
localization.
Since neither Cdc25p nor SCD25p contain a DH domain,
the mechanism of
oligomerization involving the yeast factors is
distinct from
that reported here for mammalian
GRF.
Functional relevance of oligomerization.
The possible
relevance of oligomerization to GRF function was analyzed by studying
the two GRF1 DH mutants for their transforming activity and ability to
participate in ionomycin-dependent signaling. In the NIH 3T3 cell
transformation assay, the oligomerization-competent DH cluster mutant
was less active than wild type, while oligomerization-deficient L263Q
mutant lacked any detectable activity. One interpretation of these
results is that the DH domain encodes two functions, one being
oligomerization and the other possibly involving GDP-GTP exchange
involving one or more Rho family GTPases; the oligomerization-competent DH cluster mutant, which retains some biological activity, would be
deficient only in the latter function, while the biologically inactive
L263Q mutant would be deficient in both functions. Both mutants were
deficient for calcium-dependent signaling. The precise relationship
between the DH domain of GRFs and GDP-GTP exchange on small GTP-binding
proteins remains unclear. As noted in the Introduction, negative
GDP-GTP exchange results were reported for the relationship in vitro
between GRF1 and Rho family GTPases (11a, 24), but
positive results were reported for the relationship between GRF2 and
Rac (18). However, while activation of the Rac-dependent
JNK/SAPK pathway in 293T cells was reported as being GRF2 dependent, an
activated form of Rac (RacV12) was unable to mimic this effect
(18).
Oligomerization has been reported for other components involved in
signaling. In some instances, oligomerization appears to
be primarily
inducible, such as with many cell surface receptors
(
29) and
possibly with Raf (
20,
34), while in others it
appears to be
constitutive, as with the 14-3-3 proteins (
51).
The
oligomerization of GRF1 and GRF2 identified here is constitutive.
Additional studies will be needed to determine whether it may
also have
an inducible
component.
Raf activation by Ras-dependent and Ras-independent signals.
Although GRF1 induced a constitutive increase in GTP-Ras, we observed
that the level of GTP-Ras was not augmented further when 293T cells
expressing GRF1 were treated with ionomycin, which induced a
substantial increase in Erk activity as previously reported. In seeking
an alternate explanation for the Erk activity induced by ionomycin
treatment of GRF1-expressing cells, we found that this treatment was
associated with a concomitant increase in Raf kinase activity. Given
the failure of ionomycin to increase the level of GTP-Ras, it seems
most likely that the GRF1 signal induced by ionomycin further activates
Raf via a Ras-independent pathway. The Ras-dependent activation of Raf
by GRF1 may be a prerequisite for the postulated ionomycin-mediated
Ras-independent signal that increases Raf activity, since a dominant
inhibitory mutant of Ras has been shown to inhibit the
ionomycin-dependent activation of Erk by GRF1 or GRF2 (17,
19). Thus, the ionomycin-dependent signal in the 293T cells acts
in cooperation with the constitutive GRF1 signal, which may be largely
Ras dependent.
The GTP-Ras results seen here are somewhat at variance with those
reported by Farnsworth et al. (
19), who found that ionomycin
treatment of 293T cells expressing rat GRF1 induced a small additional
increase in GTP-Ras from ca. 35% GTP-Ras without ionomycin to
ca. 43%
GTP-Ras with ionomycin (
19). It is likely that minor
differences in cells, growth conditions, and/or transfection efficiency
might account for this discrepancy. We do not view this discrepancy
as
being incompatible with the conclusion that ionomycin has induced
a
Ras-independent effect on Raf, since the small increase in GTP-Ras
seen
by Farnsworth et al. was associated with a seven- to eightfold
increase
in Erk activity. Furthermore, our in vivo results are
actually
consistent with other reported data with GRF1: ionomycin
treatment did
not lead to a further increase in the in vitro exchange
activity on Ras
in GRF1 immunoprecipitates (
19), and in vitro
calcium and
calmodulin binding to GRF1 actually inhibited Ras
exchange activity GRF
up to twofold (
2).
Although we do not yet have a detailed molecular explanation for the
Ras-independent effect on Raf, it is known that GTP-Ras,
by itself,
induces only a partial activation of Raf activity.
Additional signals,
such as the Src protein tyrosine kinase, can
cooperate with GTP-Ras to
induce higher levels of Raf kinase activity
(
16,
35).
Ca
2+ influx can activate the Ras/Raf/MAPK pathway by
diverse routes
(
14,
15,
23). In PC12 cells, which do not
express GRF, voltage-dependent
Ca
2+ influx has been
reported to activate Src (
42). Activation of
a kinase such
as Pak3, which can be activated by Cdc42 or Rac,
can also increase the
activity of Raf via the phosphorylation
of serine 338 (
32).
It is likely that the ionomycin-dependent activation of Raf depends, at
least in part, on a calmodulin-dependent activity,
such as
calmodulin-dependent kinase, given that calmodulin binding
to GRF1
depends on ionomycin, that mutation of the IQ domain in
GRF1 or GRF2
abolishes this binding, and that the ionomycin-dependent
activation of
Erk by GRF1 or GRF2 is abolished by mutation of
the IQ domain (
17,
19). However, the requirements for calmodulin-dependent
activation of GRF1 must be quite complex since, as noted above,
mutation of the other motifs in the N terminus of GRF1 attenuate
or
abolish the ionomycin-dependent activation of Erk, although
these
mutations do not prevent the ionomycin-dependent binding
of calmodulin
to
GRF1.
In summary, the results reported here imply that full GRF1 activity
requires at least two cooperative signals that activate
Raf. One is a
Ras-dependent activation, which depends primarily
on the Ras catalytic
domain in the GRF1 C terminus, although the
N terminus may also
participate. Under the growth and transfection
conditions employed
here, the Ras-dependent activity is constitutive
in NIH 3T3 and 293T
cells. However, we speculate that in neuronal
cells, where GRF is
expressed physiologically, this activity may
be repressed in the
absence of an extracellular signal and may
therefore be inducible. The
Ras-independent signal, as detected
by ionomycin treatment of 293T
cells, depends on calmodulin binding,
as well as on other functions
that depend on several motifs located
in the GRF N terminus. As
identified here, oligomerization via
its DH domain appears to be one of
these
functions.
 |
ACKNOWLEDGMENTS |
We thank Evelyn Ralston and Christine Winters from The National
Institute of Neurological Disorders and Stroke for providing neonatal
rat brains and Cheerag D. Upadhyaya for help with the preparation of figures.
P.H.A. and X.Q. contributed equally to this work.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratory of
Cellular Oncology, National Cancer Institute, Bldg. 36, Rm. 1D-32,
Bethesda, MD 20892. Phone: (301) 496-9513. Fax: (301) 480-5322. E-mail: drl{at}helix.nih.gov.
Present address: The John P. Robarts Research Institute, London,
Ontario N6A 5K8, Canada.
 |
REFERENCES |
| 1.
|
Altschul, S. F.,
T. L. Madden,
A. A. Schaffer,
J. Zhang,
Z. Zhang,
W. Miller, and D. J. Lipman.
1997.
Gapped blast and PSI-Blast: an new generation of protein database search programs.
Nucleic Acid Res.
25:3389-3402[Abstract/Free Full Text].
|
| 2.
|
Baouz, S.,
E. Jacquet,
A. Bernardi, and A. Parmeggiani.
1997.
The N-terminal moiety of CDC25Mm, a GDP/GTP exchange factor of Ras proteins, controls the activity of the catalytic domain: modulation by calmodulin and calpain.
J. Biol. Chem.
272:6671-6676[Abstract/Free Full Text].
|
| 3.
|
Boguski, M. S., and F. McCormick.
1993.
Proteins regulating Ras and its relatives.
Nature
366:643-654[Medline].
|
| 4.
|
Bowtell, D.,
P. Fu,
M. Simon, and P. Senior.
1992.
Identification of murine homologues of the Drosophila son of sevenless gene potential activators of ras.
Proc. Natl. Acad. Sci. USA
89:6511-6515[Abstract/Free Full Text].
|
| 5.
|
Brambilla, R.,
N. Gnesutta,
L. Minichiello,
G. White,
A. J. Roylance,
C. E. Herron,
M. Ramsey,
D. P. Wolfer,
V. Cestari,
C. Rossi-Arnaud,
S. G. N. Grant,
P. F. Chapman,
H. P. Lipp,
E. Sturani, and R. Klein.
1997.
A role for the Ras signalling pathway in synaptic transmission and long-term memory.
Nature
390:281-286[Medline].
|
| 6.
|
Buchsbaum, R.,
J. B. Telliez,
S. Goonesekera, and L. A. Feig.
1996.
The N-terminal pleckstrin, coiled-coil, and IQ domains of the exchange factor Ras-GRF act cooperatively to facilitate activation by calcium.
Mol. Cell. Biol.
16:4888-4896[Abstract/Free Full Text].
|
| 7.
|
Campbell, S. L.,
R. Khosravi-Far,
K. L. Rossman,
G. J. Clark, and C. J. Der.
1998.
Increasing complexity of Ras signaling.
Oncogene
17:1395-1413[Medline].
|
| 8.
|
Camus, C.,
M. Gemonat,
H. Garreau,
S. Baudet-Nessler, and M. Jacquet.
1997.
Dimerization of Cdc25p, the guanine nucleotide exchange factor for Ras from Saccharomyces cerevisiae, and its interaction with Sdc25p.
Eur. J. Biochem.
247:703-708[Medline].
|
| 9.
|
Cen, H.,
A. G. Papageorge,
W. C. Vass,
K. Zhang, and D. R. Lowy.
1993.
Regulated and constitutive activity by CDC25(Mm) (GRF), a Ras-specific exchange factor.
Mol. Cell. Biol.
13:7718-7724[Abstract/Free Full Text].
|
| 10.
|
Cen, H.,
A. G. Papageorge,
R. Zippel,
D. R. Lowy, and K. Zhang.
1992.
Isolation of multiple mouse cDNAs with coding homology to Saccharomyces cerevisiae CDC25 identification of a region related to bcr, vav, dbl and CDC24.
EMBO J.
11:4007-4015[Medline].
|
| 11.
|
Cerione, R., and Y. Zheng.
1996.
The Dbl family of oncogenes.
Curr. Opin. Cell Biol.
6:204-211.
|
| 11a.
| DeClue, J. E. Unpublished data.
|
| 12.
|
Durfee, T.,
K. Becherer,
P.-L. Chen,
S.-H. Yeh,
Y. Yang,
A. E. Kilburn,
W.-H. Lee, and S. J. Elledge.
1993.
The retinoblastoma protein associates with the protein phosphatase type I catalytic subunit.
Genes Dev.
7:555-569[Abstract/Free Full Text].
|
| 13.
|
Ebinu, J. O.,
D. A. Bottorff,
E. Y. W. Chan,
S. L. Stang,
R. J. Dunn, and J. C. Stone.
1998.
RasGRP, a Ras guanyl nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs.
Science
280:1082-1086[Abstract/Free Full Text].
|
| 14.
|
Egea, J.,
C. Espinet, and J. X. Comella.
1998.
Calmodulin modulates mitogen-activated protein kinase activation in response to membrane depolarization in PC12 cells.
J. Neurochem.
70:2554-2564[Medline].
|
| 15.
|
Enslen, H.,
H. Tokumitsu,
P. J. S. Stork,
R. J. Davis, and T. R. Soderling.
1996.
Regulation of mitogen-activated protein kinases by a calcium/calmodulin-dependent protein kinase cascade.
Proc. Natl. Acad. Sci. USA
93:10803-10808[Abstract/Free Full Text].
|
| 16.
|
Fabian, J. R.,
I. O. Daar, and D. K. Morrison.
1993.
Critical tyrosine residues regulate the enzymatic and biological activity of raf-1 kinase.
Mol. Cell. Biol.
13:7170-7179[Abstract/Free Full Text].
|
| 17.
|
Fam, N. P.,
W.-T. Fan,
Z. Wang,
L.-J. Zhang,
H. Chen, and M. F. Moran.
1996.
Cloning and characterization of Ras-GRF2, a novel guanine nucleotide exchange factor for Ras.
Mol. Cell. Biol.
17:1396-1406[Abstract/Free Full Text].
|
| 18.
|
Fan, W.-T.,
C. A. Koch,
C. L. De Hoog,
N. P. Fam, and M. F. Moran.
1998.
The exchange factor Ras-GRF2 activates Ras-dependent and Rac-dependent mitogen-activated protein kinase pathways.
Curr. Biol.
8:935-938[Medline].
|
| 19.
|
Farnsworth, C. L.,
N. W. Freshney,
L. B. Rosen,
A. Ghosh,
M. E. Greenberg, and L. A. Feig.
1995.
Calcium activation of Ras mediated by neuronal exchange factor Ras-GRF.
Nature
376:524-527[Medline].
|
| 20.
|
Farrar, M. A.,
J. Alberolaila, and R. M. Perlmutter.
1996.
Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization.
Nature
383:178-181[Medline].
|
| 21.
|
Ferrari, C.,
R. Zippel,
E. Martegani,
N. Gnesutta,
V. Carrera, and E. Sturani.
1994.
Expression of two different products of CDC25Mm, a mammalian Ras activator, during development of mouse brain.
Exp. Cell Res.
210:353-357[Medline].
|
| 22.
|
Fields, S., and O.-K. Song.
1989.
A novel genetic system to detect protein-protein interactions.
Nature
340:245-246[Medline].
|
| 23.
|
Finkbeiner, S., and M. E. Greenberg.
1996.
Ca2+-dependent routes to Ras: mechanisms for neuronal survival, differentiation, and plasticity?
Neuron
16:233-236[Medline].
|
| 24.
|
Freshney, N. W.,
S. D. Goonesekera, and L. A. Feig.
1997.
Activation of the exchange factor Ras-GRF by calcium requires an intact Dbl homology domain.
FEBS Lett.
407:111-115[Medline].
|
| 25.
|
Furth, M. E.,
L. J. Davis,
B. Fleurdelys, and E. M. Scholnick.
1982.
Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family.
J. Virol.
43:294-304[Abstract/Free Full Text].
|
| 26.
|
Guarente, L.
1983.
Yeast promoters and lacZ fusions designed to study expression of cloned genes in yeast.
Methods Enyzmol.
101:181-191.
|
| 27.
|
Guerrero, C.,
J. M. Rojas,
M. Chedid,
L. M. Esteban,
D. B. Zimonjic,
N. C. Popescu,
J. Font de Mora, and E. Santos.
1996.
Expression of alternative forms of Ras exchange factors GRF and SOS1 in different human tissues and cell lines.
Oncogene
12:1097-1107[Medline].
|
| 28.
|
Hart, M. J.,
A. Eva,
D. Zangrilli,
S. A. Aaronson,
T. Evans,
R. Cerione, and Y. Zheng.
1994.
Cellular transformation and guanine nucleotide exchange activity are catalyzed by a common domain on the dbl oncogene product.
J. Biol. Chem.
269:62-65[Abstract/Free Full Text].
|
| 29.
|
Heldin, C.
1995.
Dimerization of cell surface receptors in signal transduction.
Cell
80:213-223[Medline].
|
| 30.
|
Itier, J.-M.,
G. L. Tremp,
J.-F. Leonard,
M. C. Multon,
G. Ret,
F. Schweighoffer,
B. Tocque,
M.-T. Bluet-Pajot,
V. Cormier, and F. Dautry.
1998.
Imprinted gene in postnatal growth role.
Nature
393:125-126[Medline].
|
| 31.
|
Jacquet, E.,
S. Baouz, and A. Parmeggiani.
1995.
Characterization of mammalian C-CDC25(Mm) exchange factor and kinetic properties of the exchange reaction intermediate p21-C-CDC25(Mm).
Biochemistry
34:12347-12354[Medline].
|
| 32.
|
King, A. J.,
H. Sun,
B. Diaz,
D. Barnard,
W. Miao,
S. Bagrodia, and M. S. Marshall.
1998.
The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338.
Nature
396:180-183[Medline].
|
| 33.
|
Lowy, D. R., and B. M. Willumsen.
1993.
Function and regulation of Ras.
Annu. Rev. Biochem.
62:851-891[Medline].
|
| 34.
|
Luo, Z.,
G. Tzivion,
P. J. Belshaw,
D. Vavvas,
M. Marshall, and J. Avruch.
1996.
Oligomerization activates c-Raf-1 through a Ras-dependent mechanism.
Nature
383:181-185[Medline].
|
| 35.
|
Marais, R.,
Y. Light,
H. F. Paterson, and C. J. Marshall.
1995.
Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation.
EMBO J.
14:3136-3145[Medline].
|
| 36.
|
Marchuk, D. A.,
A. M. Saulino,
R. Tavakkol,
M. Swaroop,
M. R. Wallace,
L. B. Andersen,
A. L. Mitchell,
D. H. Gutmann,
M. Boguski, and F. S. Collins.
1991.
cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product.
Genomics
11:931-940[Medline].
|
| 37.
|
Mattingly, R. R., and I. G. Macara.
1996.
Phosphorylation-dependent activtaion of the Ras-GRF/CDC25Mm exchange factor by muscarinic receptors and G-protein beta gamma subunits.
Nature
382:268-272[Medline].
|
| 38.
|
Morrison, D., and R. J. Cutler.
1997.
The complexity of Raf-1 regulation.
Curr. Opin. Cell Biol.
9:174-179[Medline].
|
| 39.
|
Olson, M.
1996.
Guanine nucleotide exchange factors for the Rho GTPases: a role in human disease?
J. Mol. Med.
74:563-571[Medline].
|
| 40.
|
Plass, C.,
H. Shibata,
I. Kalcheva,
L. Mullins,
N. Kotelevtseva,
J. Mullins,
R. Kato,
H. Sasaki,
S. Hirotsune,
Y. Okazaki,
W. A. Held,
Y. Hayashizaki, and V. M. Chapman.
1996.
Identification of Grf1 on mouse chromosome 9 as an imprinted gene by RLGS-M.
Nat. Genet.
14:106-109[Medline].
|
| 41.
|
Qian, X.,
W. C. Vass,
A. G. Papageorge,
P. H. Anborgh, and D. R. Lowy.
1998.
N terminus of Sos1 Ras exchange factor: critical roles for the Dbl and pleckstrin homology domains.
Mol. Cell. Biol.
18:771-778[Abstract/Free Full Text].
|
| 42.
|
Rusanescu, G.,
H. Qi,
S. M. Thomas, and J. S. H. Brugge.
1995.
Calcium influx induces neurite growth through a Src-Ras signaling cassette.
Neuron
15:1415-1425[Medline].
|
| 43.
|
Schweighoffer, F.,
M. Faure,
I. Fath,
M. C. Chevallier-Multon,
F. Apiou,
B. Dutrillaux,
E. Sturani,
M. Jacquet, and B. Tocque.
1993.
Identification of a human guanine nucleotide-releasing factor (H-GRF55) specific for Ras proteins.
Oncogene
8:1477-1485[Medline].
|
| 44.
|
Shou, C.,
C. L. Farnsworth,
B. G. Neel, and L. A. Feig.
1992.
Molecular cloning of cDNAs encoding a guanine-nucleotide-releasing factor for Ras p21.
Nature
358:351-354[Medline].
|
| 45.
|
Simon, M. A.,
D. D. L. Bowtell,
G. S. Dodson,
T. R. Laverty, and G. M. Rubin.
1991.
Ras1 and a putative guanine nucleotide exchange factor perform crucial steps in signaling by the sevenless protein tyrosine kinase.
Cell
67:701-716[Medline].
|
| 46.
|
Soisson, S. M.,
A. S. Nimnual,
M. Uy,
D. Bar-Sagi, and J. Kuriyan.
1998.
Crystal structure of the Dbl and pleckstrin homology domains from the human son of sevenless protein.
Cell
95:259-268[Medline].
|
| 47.
|
Sturani, E.,
A. Abbondio,
P. Branduardi,
C. Ferrari,
R. Zippel,
E. Martegani,
M. Vanoni, and S. Denis-Donini.
1997.
The Ras guanine nucleotide exchange factor CDC25Mm is present at the synaptic junction.
Exp. Cell Res.
235:117-123[Medline].
|
| 48.
|
Tognon, C. E.,
H. E. Kirk,
L. A. Passmore,
I. P. Whitehead,
C. J. Der, and R. J. Kay.
1998.
Regulation of RasGRP via a phorbol ester-responsive C1 domain.
Mol. Cell. Biol.
18:6995-7008[Abstract/Free Full Text].
|
| 49.
|
Touhara, K.,
J. Inglese,
J. Pitcher,
G. Shaw, and R. J. Lefkowitz.
1994.
Binding of G protein beta gamma-subunits to pleckstrin homology domains.
J. Biol. Chem.
264:10217-10220[Abstract/Free Full Text].
|
| 50.
|
Tung, P. S.,
N. P. Fam,
L. Chen, and M. F. Moran.
1997.
A 54-kDa protein related to ras-guanine nucleotide release factor expressed in the rat exocrine pancreas.
Cell Tissue Res.
289:505-515[Medline].
|
| 51.
|
Tzivion, G.,
Z. Luo, and J. Avruch.
1998.
A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity.
Nature
394:88-92[Medline].
|
| 52.
|
Van Aelst, L., and C. D'Souza-Schorey.
1997.
The Rho GTPases and signaling networks.
Genes Dev.
11:2295-2322[Free Full Text].
|
| 53.
|
Willumsen, B. M.,
W. C. Vass,
T. J. Velu,
A. G. Papageorge,
J. Schiller, and D. R. Lowy.
1991.
The BPV E5 oncogne can cooperate with ras: identification of a p21 amino acid segment required for transformation by c-rasH but not v-rasH.
Mol. Cell. Biol.
11:6026-6033[Abstract/Free Full Text].
|
| 54.
|
Zhang, K.,
A. G. Papageorge, and D. R. Lowy.
1992.
Mechanistic aspects of signalling through Ras in NIH 3T3 cells.
Science
257:671-674[Abstract/Free Full Text].
|
Molecular and Cellular Biology, July 1999, p. 4611-4622, Vol. 19, No. 7
0270-7306/99/$04.00+0
This article has been cited by other articles:
-
Mionnet, C., Bogliolo, S., Arkowitz, R. A.
(2008). Oligomerization Regulates the Localization of Cdc24, the Cdc42 Activator in Saccharomyces cerevisiae. J. Biol. Chem.
283: 17515-17530
[Abstract]
[Full Text]
-
Ruiz, S., Santos, E., Bustelo, X. R.
(2007). RasGRF2, a Guanosine Nucleotide Exchange Factor for Ras GTPases, Participates in T-Cell Signaling Responses. Mol. Cell. Biol.
27: 8127-8142
[Abstract]
[Full Text]
-
Zhu, T.-N., He, H.-J., Kole, S., D'Souza, T., Agarwal, R., Morin, P. J., Bernier, M.
(2007). Filamin A-mediated Down-regulation of the Exchange Factor Ras-GRF1 Correlates with Decreased Matrix Metalloproteinase-9 Expression in Human Melanoma Cells. J. Biol. Chem.
282: 14816-14826
[Abstract]
[Full Text]
-
Anborgh, P. H., Godin, C., Pampillo, M., Dhami, G. K., Dale, L. B., Cregan, S. P., Truant, R., Ferguson, S. S. G.
(2005). Inhibition of Metabotropic Glutamate Receptor Signaling by the Huntingtin-binding Protein Optineurin. J. Biol. Chem.
280: 34840-34848
[Abstract]
[Full Text]
-
Leaner, V. D., Donninger, H., Ellis, C. A., Clark, G. J., Birrer, M. J.
(2005). p75-Ras-GRF1 Is a c-Jun/AP-1 Target Protein: Its Up Regulation Results in Increased Ras Activity and Is Necessary for c-Jun-Induced Nonadherent Growth of Rat1a Cells. Mol. Cell. Biol.
25: 3324-3337
[Abstract]
[Full Text]
-
Baisamy, L., Jurisch, N., Diviani, D.
(2005). Leucine Zipper-mediated Homo-oligomerization Regulates the Rho-GEF Activity of AKAP-Lbc. J. Biol. Chem.
280: 15405-15412
[Abstract]
[Full Text]
-
Kim, J.-E., Billadeau, D. D., Chen, J.
(2005). The Tandem BRCT Domains of Ect2 Are Required for Both Negative and Positive Regulation of Ect2 in Cytokinesis. J. Biol. Chem.
280: 5733-5739
[Abstract]
[Full Text]
-
Robinson, K. N., Manto, K., Buchsbaum, R. J., MacDonald, J. I. S., Meakin, S. O.
(2005). Neurotrophin-dependent Tyrosine Phosphorylation of Ras Guanine-releasing Factor 1 and Associated Neurite Outgrowth Is Dependent on the HIKE Domain of TrkA. J. Biol. Chem.
280: 225-235
[Abstract]
[Full Text]
-
Kunita, R., Otomo, A., Mizumura, H., Suzuki, K., Showguchi-Miyata, J., Yanagisawa, Y., Hadano, S., Ikeda, J.-E
(2004). Homo-oligomerization of ALS2 through Its Unique Carboxyl-terminal Regions Is Essential for the ALS2-associated Rab5 Guanine Nucleotide Exchange Activity and Its Regulatory Function on Endosome Trafficking. J. Biol. Chem.
279: 38626-38635
[Abstract]
[Full Text]
-
Meller, N., Irani-Tehrani, M., Ratnikov, B. I., Paschal, B. M., Schwartz, M. A.
(2004). The Novel Cdc42 Guanine Nucleotide Exchange Factor, Zizimin1, Dimerizes via the Cdc42-binding CZH2 Domain. J. Biol. Chem.
279: 37470-37476
[Abstract]
[Full Text]
-
Buck, C. B., Pastrana, D. V., Lowy, D. R., Schiller, J. T.
(2004). Efficient Intracellular Assembly of Papillomaviral Vectors. J. Virol.
78: 751-757
[Abstract]
[Full Text]
-
Eisenhaure, T. M., Francis, S. A., Willison, L. D., Coughlin, S. R., Lerner, D. J.
(2003). The Rho Guanine Nucleotide Exchange Factor Lsc Homo-oligomerizes and Is Negatively Regulated through Domains in Its Carboxyl Terminus That Are Absent in Novel Splenic Isoforms. J. Biol. Chem.
278: 30975-30984
[Abstract]
[Full Text]
-
Yang, H., Cooley, D., Legakis, J. E., Ge, Q., Andrade, R., Mattingly, R. R.
(2003). Phosphorylation of the Ras-GRF1 Exchange Factor at Ser916/898 Reveals Activation of Ras Signaling in the Cerebral Cortex. J. Biol. Chem.
278: 13278-13285
[Abstract]
[Full Text]
-
Jorge, R., Zarich, N., Oliva, J. L., Azanedo, M., Martinez, N., de la Cruz, X., Rojas, J. M.
(2002). hSos1 Contains a New Amino-terminal Regulatory Motif with Specific Binding Affinity for Its Pleckstrin Homology Domain. J. Biol. Chem.
277: 44171-44179
[Abstract]
[Full Text]
-
Pusl, T., Wu, J. J., Zimmerman, T. L., Zhang, L., Ehrlich, B. E., Berchtold, M. W., Hoek, J. B., Karpen, S. J., Nathanson, M. H., Bennett, A. M.
(2002). Epidermal Growth Factor-mediated Activation of the ETS Domain Transcription Factor Elk-1 Requires Nuclear Calcium. J. Biol. Chem.
277: 27517-27527
[Abstract]
[Full Text]
-
Schmidt, A., Hall, A.
(2002). Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev.
16: 1587-1609
[Full Text]
-
Gnesutta, N., Ceriani, M., Innocenti, M., Mauri, I., Zippel, R., Sturani, E., Borgonovo, B., Berruti, G., Martegani, E.
(2001). Cloning and Characterization of Mouse UBPy, a Deubiquitinating Enzyme That Interacts with the Ras Guanine Nucleotide Exchange Factor CDC25Mm/Ras-GRF1. J. Biol. Chem.
276: 39448-39454
[Abstract]
[Full Text]
-
Zhu, K., Debreceni, B., Bi, F., Zheng, Y.
(2001). Oligomerization of DH Domain Is Essential for Dbl-Induced Transformation. Mol. Cell. Biol.
21: 425-437
[Abstract]
[Full Text]
-
de Hoog, C. L., Fan, W.-T., Goldstein, M. D., Moran, M. F., Koch, C. A.
(2000). Calmodulin-Independent Coordination of Ras and Extracellular Signal-Regulated Kinase Activation by Ras-GRF2. Mol. Cell. Biol.
20: 2727-2733
[Abstract]
[Full Text]
-
Chen, R. A., Michaeli, T., Van Aelst, L., Ballester, R.
(2000). A Role for the Noncatalytic N Terminus in the Function of Cdc25, a Saccharomyces cerevisiae Ras-Guanine Nucleotide Exchange Factor. Genetics
154: 1473-1484
[Abstract]
[Full Text]
-
Kiyono, M., Kaziro, Y., Satoh, T.
(2000). Induction of Rac-Guanine Nucleotide Exchange Activity of Ras-GRF1/CDC25Mm following Phosphorylation by the Nonreceptor Tyrosine Kinase Src. J. Biol. Chem.
275: 5441-5446
[Abstract]
[Full Text]
-
Mattingly, R. R.
(1999). Phosphorylation of Serine 916 of Ras-GRF1 Contributes to the Activation of Exchange Factor Activity by Muscarinic Receptors. J. Biol. Chem.
274: 37379-37384
[Abstract]
[Full Text]
-
Kiyono, M., Kato, J., Kataoka, T., Kaziro, Y., Satoh, T.
(2000). Stimulation of Ras Guanine Nucleotide Exchange Activity of Ras-GRF1/CDC25Mm upon Tyrosine Phosphorylation by the Cdc42-regulated Kinase ACK1. J. Biol. Chem.
275: 29788-29793
[Abstract]
[Full Text]
-
Arozarena, I., Aaronson, D. S., Matallanas, D., Sanz, V., Ajenjo, N., Tenbaum, S. P., Teramoto, H., Ighishi, T., Zabala, J. C., Gutkind, J. S., Crespo, P.
(2000). The Rho Family GTPase Cdc42 Regulates the Activation of Ras/MAP Kinase by the Exchange Factor Ras-GRF. J. Biol. Chem.
275: 26441-26448
[Abstract]
[Full Text]